Cisplatin plus gemcitabine with or without vinorelbine as neoadjuvant therapy for radically treatable stage III non small cell lung cancer (NSCLC). Preliminary results of a randomised study of the GON (Grupo Oncológico del Norte de España)

Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art

“…Radiation recall events are usually cutaneous or mucosal reactions or pneumonitis in the treatment field of prior radiotherapy that are precipitated by drug treatment; these events have been reported with many cytotoxic drugs, such as doxorubicin, etoposide, paclitaxel, and tamoxifen [16]. The cutaneous reports were primarily skin erythema and pruritus [15][16][17][18], while the noncutaneous reactions included hepatic necrosis [19], optic neuritis, brainstem radio necrosis, lymphangitis [18], and abdominal wall tenderness [18,20]. In general, radiation recall events have been rarely reported with gemcitabine [16,18].…”

“…Full-dose gemcitabine-based combinations have been studied in the induction setting in several trials. The majority of published data is with gemcitabine and cisplatin [14,[19][20][21][22], although there are also published studies of gemcitabine and carboplatin [23][24][25][26][27][28], vinorelbine [29], and triplet therapy with paclitaxel and a platinum agent [30][31][32]. Most studies used two to three cycles of induction.…”

“…In randomized studies, the combination of gemcitabine and cisplatin has been compared with another cisplatin-based combination, either with etoposide, vinorelbine, or paclitaxel [14,[19][20][21][22]. The gemcitabine dose used in most of these studies was 1250 mg/m 2 on days 1 and 8, while the cisplatin dose ranged from 50 to 100 mg/m 2 on day 1 every 21 days.…”